Last reviewed · How we verify
NCT06964737
Anti-GARP Chimeric Antigen Receptor T Cell Therapy for the Treatment of Recurrent Grade III or IV Gliomas
Phase 1 trial testing Anti-GARP Chimeric Antigen Receptor-T Cells in Recurrent Malignant Glioma in 30 participants. Currently enrolling.
31 December 2026
Quick facts
| Lead sponsor | Ohio State University Comprehensive Cancer Center |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 21 May 2025 |
| Primary completion | 31 December 2026 |
| Estimated completion | 31 December 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Anti-GARP Chimeric Antigen Receptor-T Cells — full drug profile →
- Biospecimen Collection — full drug profile →
- Chest Radiography
- Echocardiography Test
- Magnetic Resonance Imaging
- Multigated Acquisition Scan
- Pheresis
- Surgical Procedure
Conditions studied
- Recurrent Malignant Glioma — all drugs for Recurrent Malignant Glioma →
- Recurrent WHO Grade 3 Glioma — all drugs for Recurrent WHO Grade 3 Glioma →
- Recurrent WHO Grade 4 Glioma — all drugs for Recurrent WHO Grade 4 Glioma →
- WHO Grade 2 Glioma — all drugs for WHO Grade 2 Glioma →
Sponsor
Ohio State University Comprehensive Cancer Center
Who can join
18 and older, any sex, with Recurrent Malignant Glioma or Recurrent WHO Grade 3 Glioma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This phase I trial tests the safety, side effects, and best dose of anti-glycoprotein-A repetitions predominant (GARP) chimeric antigen receptor (CAR) T cell therapy and how well it works in treating patients with grade III or IV gliomas that have come back after a period of improvement (recurrent). CAR T-cell therapy is a type of treatment in which a patient's T cells (a type of immune system cell) are changed in the laboratory so they will attack tumor cells. T cells are taken from a patient's blood. Then the gene for a special receptor that binds to a certain protein, such as GARP, on the patient's tumor cells is added to the T cells in the laboratory. The special receptor is called a CAR. Large numbers of the CAR T cells are grown in the laboratory and given to the patient by infusion for treatment of certain tumors. Giving anti-GARP CAR T cell therapy may be safe, tolerable, and/or effective in treating patients with recurrent grade III or IV gliomas.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Targeting TGFβ docking receptor glycoprotein A repetitions predominant (GARP) via novel chimeric antigen receptor (CAR)-T cell platform to treat glioblastoma.
Wu BX, Kreatsoulas D, Cam H, Bolyard C, et al · · 2025 · cited 2× · PMID 40873341 · DOI 10.1093/neuonc/noaf195
Verify or expand the search:
- PubMed search for NCT06964737
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Recurrent Malignant Glioma
Currently open trials in the same condition.
- NCT07448480 — Comprehensive Analysis of Chemotherapy and Targeted Therapy Outcomes in Recurrent Malignant Gliomas · active not recruiting
- NCT05045027 — Simultaneous Multinuclear Metabolic MRI in Newly Diagnosed or Recurrent Glioma · EARLY_PHASE1 · active not recruiting
- NCT04320888 — Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene A · Phase 2 · active not recruiting
- NCT04284774 — Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a · Phase 2 · active not recruiting
- NCT04323046 — Immunotherapy Before and After Surgery for Treatment of Recurrent or Progressive High Grade Glioma in Children and Young · Phase 1 · recruiting
Other Ohio State University Comprehensive Cancer Center trials
Trials by the same sponsor.
- NCT06816979 — Lumbar Punctures for the Detection of ctDNA in the Cerebrospinal Fluid of Patients With Stage III and IV Non-Small Cell · NA · not yet recruiting
- NCT07529483 — Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cysts · Phase 2 · not yet recruiting
- NCT07455513 — A Novel Tobacco Cessation Resource for Smokers With a Diagnosed or Suspected Thoracic Cancer · NA · not yet recruiting
- NCT07217990 — Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer · Phase 1, PHASE2 · not yet recruiting
- NCT07503925 — THRIVE Study: Understanding How Oral Nicotine Pouches Affect Public Health · Phase 4 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06964737 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ohio State University Comprehensive Cancer Center
- Last refreshed: 29 October 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06964737.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing